DVADaVita
Price
+38%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, undemanding price, growth steady, the market undecided.
DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, we have been a leader in clinical quality and innovation for more than 25 years. We care for patients at every stage and setting along their kidney health journey–from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in our dialysis centers, in the hospital and in skilled nursing facilities.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
DaVita (DVA) reported revenue of $3.55B in Q2 2026 (quarter ended Jun 30, 2026), up 5.2% from the same quarter a year earlier. That came with net income of $265M (7.5% of revenue). For the full year FY2025, revenue was $13.6B (+6.5% year on year) and net income $747M. Its largest segment in Q2 2026 was U.S.Dialysis With Intersegment at $2.99B, 56% of the disclosed total, well ahead of U.S.Dialysis And Related Lab Services at 33%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026DaVita Inc. 2nd Quarter 2026 Results.Earnings release · press release
- Jun 8, 2026On June 8, 2026, DaVita Inc. (the “Company”) entered into a Ninth Amendment (the “Ninth Amendment”) to that certain Credit Agreement dated as of August 12, 2019 (as previously amended, restated, supplemented, or otherwise modified, and as further amended by the Ninth Amendment, the “Credit Agreement”), by and among …Material agreement entered · Form 8-K
- May 5, 2026DaVita Inc. 1st Quarter 2026 Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $5.35BThe company’s own SEC segment disclosure.
- U.S.Dialysis With Intersegment$2.99B56%
- U.S.Dialysis And Related Lab Services$1.75B33%
- Other Operating Segments With Intersegment$372.4M7%
- All Other$236.4M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Care Facilities
The closest names by size in the same industry